Longevity Health Holdings, Inc. (XAGE) has entered into a definitive merger agreement with True Health Inc in an all-stock transaction. Upon closing, the combined entity will continue trading on Nasdaq under the symbol XAGE..
This merger with THPlasma follows Longevity Therapeutics’ acquisitions of Carmell Therapeutics in July 2023 and Elevai Skincare in January 2025, with the transaction expected to close in Q4 2025.
Mr. George Chi, Founder and CEO of THPlasma, expressed excitement about the merger, calling it a transformative step poised to accelerate growth by providing access to public markets and future M&A opportunities.
Additionally, Longevity announced the mutual termination of the 20/20 BioLabs transaction as outlined in the merger agreement.
